Compliance 13 min read

Preventing Unnotified NDI Adulteration: Controls from a Warning Letter

J

October 28, 2026

If your supplement label lists an ingredient, you need a documented answer to one question before launch: is this ingredient old or new, and if it is new, does it qualify for the food-supply exemption or has a notification been filed with FDA? A warning letter FDA posted in connection with a September 29, 2026 action against a supplement marketer appears to illustrate what happens when nobody asked that question. As I read the posted text, the agency pointed to labeling that declared Amanita muscaria extract as a dietary ingredient and concluded the products were adulterated under section 402(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). You can read the letter on FDA's warning letter page.

I am not going to retell that company's story. The more useful exercise is to ask what quality system would have caught this problem before a single unit shipped, because the same gap sits inside a lot of supplement businesses, especially the ones chasing a trending botanical.

What Does the Law Say About a New Dietary Ingredient?

The Dietary Supplement Health and Education Act of 1994 (DSHEA) drew a line at October 15, 1994. An ingredient marketed as a dietary supplement in the United States before that date is generally treated as an "old" dietary ingredient. Anything else is a "new dietary ingredient," or NDI, defined in section 413(d) of the FD&C Act (21 U.S.C. 350b(d)).

Section 413(a) (21 U.S.C. 350b(a)) then sets the rule that trips up so many firms. Section 413 applies only to NDIs, so an ingredient marketed before October 15, 1994 sits outside it entirely. A supplement containing an NDI is adulterated under section 402(f)(1)(B) unless one of two things is true:

  1. The ingredient has been present in the food supply as an article used for food in a form that has not been chemically altered, or
  2. The manufacturer or distributor submitted a premarket notification to FDA at least 75 days before introducing the product, with information providing a basis to conclude the ingredient is reasonably expected to be safe under its conditions of use.

The notification procedure lives at 21 CFR 190.6. FDA does not "approve" an NDI notification. It reviews the submission and either objects or does not, and the agency has been explicit that a notification without objection is not an endorsement. The point for your quality system is that the burden of establishing the ingredient's status sits with the firm, not with FDA.

The statute makes this a product-level adulteration issue, so no manufacturing defect or contamination event is required. A product can be made perfectly under 21 CFR Part 111 and still be adulterated the day it is introduced into interstate commerce, because the ingredient itself lacked the required notification.

Why Did This Warning Letter Focus on Labeling?

This is the detail I find most instructive. The letter's focus on the declared ingredient suggests FDA did not need a lab result or an inspection finding to start its analysis. I am inferring that the agency measured the company's own labeling declaration against the ingredient's marketing history and the NDI notifications on file; the letter should be read directly for what it actually cites.

A supplement label is a public statement of ingredient identity. Under 21 CFR 101.36, the Supplement Facts panel and ingredient statement have to name each dietary ingredient. Once you name it, you have handed a regulator the starting point for an adulteration case. If the ingredient is new and unnotified, the label becomes the evidence.

That is why I tell clients that ingredient review has to happen before label design, not after. Once artwork is approved and inventory is printed, the commercial pressure to "make it work" is intense.

What Is the Difference Between Adulterated and Misbranded Here?

People often blur these. They are separate legal theories, and a single product can be both.

Issue Legal basis What triggers it Typical response
Adulterated: unnotified NDI FD&C Act 402(f)(1)(B); 413(a); 21 CFR 190.6 Ingredient not marketed before Oct 15, 1994 and no 75-day notification Stop distribution; file a notification or reformulate before resuming
Adulterated: cGMP failure FD&C Act 402(g)(1); 21 CFR Part 111 Manufacturing, packaging, labeling or holding not under Part 111 controls Corrective actions across the Part 111 system
Misbranded: labeling FD&C Act 403; 21 CFR 101.36 False or missing Supplement Facts, ingredient or identity statements Correct the label going forward; product already in commerce may need correction or removal

The first row is the one that does not get enough attention in cGMP-focused programs. Some firms have decent Part 111 records and no process whatsoever for deciding whether an ingredient is lawful in the first place.

Which Controls Would Have Prevented This?

Here is where I would spend effort. None of it is exotic, and most of it fits inside a system you already have under Part 111 or a general quality management framework.

An ingredient eligibility gate before development starts

Create a written procedure that no new ingredient can enter formulation until it passes a documented status review. The review file should answer these questions:

  • Is there documented evidence of marketing as a dietary supplement in the United States before October 15, 1994? Catalogs, invoices, dated labels and trade publications count. A supplier's assertion does not.
  • If not, is there an NDI notification on file that FDA reviewed without objection, and does it cover your specific form, dose, and conditions of use?
  • If the ingredient was present in the food supply, can you show it was used in a form that was not chemically altered? An extract is a processed form, so this question needs real attention rather than a quick yes.
  • Is the substance excluded from the dietary supplement definition in section 201(ff)(3)(B) of the FD&C Act, for example because it was first studied or approved as a drug?
  • Has FDA stated a position on this ingredient in a warning letter, import alert, or public communication?

That last question costs almost nothing to answer. Searching FDA's warning letter database for the ingredient name takes an afternoon and can save a launch.

A certificate of analysis tells you what is in the material. It says nothing about whether the material is a lawful dietary ingredient. Under 21 CFR 111.75(a), you have to verify the identity of dietary ingredients and confirm specifications are met, and that is a quality question. Lawfulness is a regulatory question, and I would assign it to a named person with authority to stop a project. In many small companies those two roles collapse into one overworked person, which is how the legal question gets skipped.

Tie label approval to the ingredient file

Require that the label approval record cite the completed ingredient status review. If regulatory sign-off on the ingredient is missing, the label does not move to print. This is a simple document-control link, and it forces the conversation at the point where reversing course is still cheap.

Watch the trend cycle

Ingredients that get popular fast tend to be the ones with unclear regulatory status, because demand arrives before the paperwork does. If a product idea comes from a social media trend or a competitor's launch, I would treat that as a flag to look harder, not a reason to hurry. The competitor may be exposed to the same enforcement action you are about to invite.

Write the product's safety rationale down

Even if you conclude an ingredient is old or exempt, keep the reasoning in a file. If FDA later questions your position, a dated memo with supporting documents is a very different conversation from an executive recalling why the team felt comfortable. For ingredients with pharmacological activity, FDA will expect the safety discussion to be substantive.

What If You Think the Ingredient Needs an NDI Notification?

Plan on the 75-day clock. Section 413(a)(2) requires submission at least 75 days before the product is introduced or delivered for introduction into interstate commerce. That means your launch calendar should include notification time as a fixed dependency, not a variable you can compress.

Under 21 CFR 190.6(b), a notification has to include the submitter's identity, the ingredient's name, a description of the dietary supplement(s) containing it including the level of use and conditions of use, and the history of use or other evidence of safety establishing that the ingredient is reasonably expected to be safe under those conditions. FDA first conducts a filing review for completeness, then has 75 days from receipt to respond. FDA has published guidance on NDI notifications and on determining whether an ingredient is an NDI, and I would read the current version before you draft anything. FDA can respond that the notification is incomplete or that the information does not establish safety, and a firm that markets after an objection is in a very exposed position.

I would also be careful about the temptation to file and ship on day 76 regardless of the agency's response. The statute sets the earliest date you can market. FDA can object within the 75 days, and it does not guarantee the agency agrees with your safety conclusion.

What Happens After a Warning Letter Like This?

FDA warning letters customarily ask the recipient to respond in writing within 15 business days with corrective actions. That is FDA's standard request, not a legal deadline, but ignoring it invites escalation. For an adulteration problem rooted in the ingredient itself, the options narrow quickly. You can stop selling the product, you can reformulate to remove the ingredient, or you can pursue a notification and hold the product until the process is resolved. Continuing to ship while arguing about the law is the path that leads to seizure, injunction, or other enforcement under the FD&C Act, including seizure (section 304), injunction (section 302), and prosecution for prohibited acts under section 301(a).

There are also costs that never appear in the letter. Retailers and marketplaces watch these postings, payment processors and insurers do too, and inventory already in the channel may need to be pulled. If you are in this position, our warning letter remediation page describes how we structure a response, and the same fundamentals apply to supplements as to other regulated products: scope the problem honestly, fix the cause, and commit to dates you can keep.

For a deeper look at how the agency separates an inspectional observation from a formal enforcement step, see our article on FDA warning letters versus Form 483 observations.

How Should You Audit Your Current Portfolio?

If you read this and felt a small knot in your stomach about one of your SKUs, I think that is a useful instinct. Here is a practical way to turn it into action this month:

  1. Export a list of every dietary ingredient across all active SKUs, including botanical extracts, blends, and "proprietary" components.
  2. For each, locate the status file. If one does not exist, build it. If you cannot build one, flag the ingredient as high risk.
  3. Rank flagged ingredients by sales volume and by the strength of the evidence you have, and start with the ones where both exposure and uncertainty are high.
  4. Check each ingredient against FDA's warning letter database and recent public statements.
  5. Decide for each flagged item: document the basis for status, file a notification, reformulate, or discontinue.
  6. Update your new-product procedure so the gate exists going forward.

When you go through this, you may find that some "old" ingredients are only old in one form. A traditional whole herb can be an old dietary ingredient while a concentrated extract made by a new process may raise a separate question. That nuance is exactly why a form-by-form review matters.

Where Does This Fit With Everything Else FDA Expects?

I do not want to leave the impression that NDI status is the only way a supplement gets into trouble. Structure/function claims that drift into disease claims, undeclared drug ingredients, and Part 111 failures all generate warning letters, and our piece on structure/function versus drug claims covers the claim side of the picture. What makes the NDI problem different is that it sits upstream of everything. If the ingredient is not lawful to sell, flawless batch records do not rescue the product.

The habit that matters is treating "are we allowed to sell this?" as a quality system input with an owner and a record. If you want a second set of eyes on an ingredient file before a label goes to print, you can reach us through Certify Consulting.

Frequently Asked Questions

What makes a dietary supplement adulterated under section 402(f)(1)(B)?

A supplement is adulterated under 402(f)(1)(B) when it contains a new dietary ingredient and the firm has neither shown the ingredient was present in the food supply in a non-chemically-altered form nor submitted a premarket notification to FDA at least 75 days before marketing, as section 413(a) requires.

How do I know if an ingredient is a new dietary ingredient?

An ingredient is an NDI if it was not marketed in the United States as a dietary supplement before October 15, 1994. FDA does not publish a definitive list of pre-1994 ingredients, so you have to build evidence such as dated catalogs, invoices, or labels showing sales before that date, and review FDA guidance on NDIs.

Does FDA approve an NDI notification?

No. FDA reviews a notification under 21 CFR 190.6 and responds, but it does not approve the ingredient. A response without objection does not mean the agency has endorsed the product, and the firm remains responsible for the safety and lawful status of what it sells.

Can a supplement be adulterated even if the facility follows 21 CFR Part 111?

Yes. Part 111 governs how a supplement is manufactured, packaged, labeled, and held. An unnotified NDI makes the product adulterated under 402(f)(1)(B) regardless of how well it was made, which is why ingredient status review needs to sit alongside your cGMP program.

How long do I have to respond to an FDA warning letter?

FDA warning letters ordinarily ask for a written response within 15 business days of receipt. This is FDA's customary request rather than a statutory deadline. The response should describe specific corrective actions, include supporting documents, and give realistic completion dates.

Last updated: 2026-10-28

J

Jared Clark

Principal Consultant, Certify Consulting

Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.

Need Help Now? Don't Wait for the Blog.

If you're facing an FDA inspection, responding to a warning letter, or navigating a regulatory submission — schedule a free consultation with Jared Clark. Expert guidance, no obligation.